This website is best viewed using the horizontal display on your tablet device.
This site is intended for U.S. healthcare professionals.
Indication
IDHIFA® (enasidenib) is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 mutation as detected by an FDA-approved test.
This website is best viewed using the horizontal display on your tablet device.
This website is best viewed using the vertical display on your mobile device.
Clinical Resources
WATCH A THEORETICAL PATIENT CASE AND RESULTS FROM THE PIVOTAL TRIAL
View two experts discussing a theoretical patient with R/R AML who received IDHIFA® and outcomes from the IDHIFA® pivotal trial.
Dr Hetty Carraway and Dr Daniel A Pollyea have been paid by Bristol Myers Squibb to participate in this video.
Dr Hetty Carraway is an Associate Professor of Medicine at the Cleveland Clinic.
Dr Daniel A Pollyea is an Associate Professor of Medicine and Clinical Director of Leukemia Services, Division of Hematology at the University of Colorado School of Medicine.
WATCH THE MECHANISM OF ACTION OF ENASIDENIB TARGETING THE IDH2 MUTATION IN AML
Take a look at the role of mutated IDH2 in AML and a targeted approach with enasidenib for patients who have R/R AML with an IDH2 mutation.
WATCH AN EXPERT DISCUSS DIFFERENTIATION SYNDROME AND OTHER ADVERSE EVENTS ASSOCIATED WITH IDHIFA®
Explore important topics in managing patients who have R/R AML with an IDH2 mutation receiving IDHIFA®, including diagnosing and treating differentiation syndrome and other adverse events.
Dr Harry Erba and Marilyn Pritchard, RN, have been paid by Bristol Myers Squibb to participate in this video.
Patient & Caregiver Resources